The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ELVN | +24.35% | -49.21% | -12.66% | +11% |
| S&P | +14.29% | +86.82% | +13.3% | +75% |
Enliven Therapeutics, Inc. operates as a clinical stage precision oncology company. It is focused on the discovery and development of next-generation small molecule kinase inhibitors and advancing Enliven's pipeline of precision oncology product candidates. The company was founded in June 2019 and is headquartered in Boulder, CO.
The Chief Scientific Officer of this biopharmaceutical company sold 20,000 shares in mid-January 2026, amid the company's stock rising 71% throughout the month.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$62.00K | 22.5% |
| Market Cap | $1.21B | 0.5% |
| Market Cap / Employee | $18.65M | -19.6% |
| Employees | 65 | 14.0% |
| Net Income | -$20,148.00K | 13.0% |
| EBITDA | -$25,034.00K | 7.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $101.73M | 1.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | 0.0% |
| Short Term Debt | $387.00K | 355.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -24.41% | 5.0% |
| Return On Invested Capital | -36.32% | -15.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$13,278.00K | -8.7% |
| Operating Free Cash Flow | -$13,279.00K | -8.9% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.69 | 3.11 | 3.41 | 2.48 | -37.18% |
| Price to Tangible Book Value | 3.69 | 3.11 | 3.41 | 2.48 | -37.18% |
| Enterprise Value to EBITDA | -30.14 | -22.01 | -19.48 | -31.71 | -9.04% |
| Return on Equity | -32.0% | -31.3% | -25.3% | -25.4% | -17.91% |
| Total Debt | $0.00K | $365.00K | $376.00K | $387.00K | 355.29% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
